Antibiotic prescribing and resistance beyond hospital surveillance networks in India
This study utilizes a large-scale digital healthcare platform in India to reveal significant gaps in community-based antibiotic surveillance, highlighting high prescribing rates of Watch and Not Recommended antibiotics alongside concerning resistance patterns in urinary *E. coli*, thereby demonstrating the value of non-hospital data for guiding antimicrobial stewardship.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the invisible world of bacteria, a silent war is being waged against the medicines designed to stop them. For decades, doctors have relied on a set of rules to decide which antibiotic to use for a specific infection. These rules sort drugs into three groups based on how important they are for human health. The first group, called "Access," contains the most common, first-line medicines that are effective and safe for most people. The second group, "Watch," includes stronger drugs that are reserved for more serious infections because they carry a higher risk of bacteria becoming resistant to them. The third group, "Reserve," holds the strongest weapons, saved only for when nothing else works. The goal of global health is to keep the use of the first group high, ensuring that the powerful second and third groups remain effective when truly needed. However, tracking how these drugs are actually used outside of hospitals has been difficult. Most data comes from large medical centers, leaving a blind spot regarding what happens in the broader community where people get their medicine and tests.
A new study has filled part of that gap by looking at millions of records from a digital health platform in India. Instead of relying on hospital reports, the researchers examined data from a vast network of online pharmacies and home-based diagnostic services. They analyzed 2.78 million antibiotic prescriptions and nearly 156,000 microbiology samples collected between 2023 and 2025. This approach allowed them to see a different side of the story: what people are actually buying and what bacteria are found in their homes, rather than just what is happening inside clinic walls. The study focused heavily on urine samples, which made up almost all the tests, to understand how common infections are responding to treatment in the community.
The researchers found a clear imbalance in how antibiotics are being prescribed. Across the regions they studied, the "Watch" drugs, which are meant to be used more cautiously, accounted for nearly half of all prescriptions. In contrast, the preferred "Access" drugs made up less than one-third of the total. This pattern held true across almost every state and territory included in the analysis, with none of them reaching the global target of having at least 60 percent of prescriptions be "Access" drugs. The data showed that while doctors and patients are turning to stronger medicines, the most basic, effective options are being used less often than health guidelines recommend.
When the team looked at the bacteria found in the urine samples, they discovered that resistance levels varied wildly depending on the specific drug and the type of bacteria. For the most common bacteria found, Escherichia coli, resistance to the preferred "Access" drug nitrofurantoin was very low, at about 5 percent. However, resistance to the "Watch" drugs ceftriaxone and ciprofloxacin was extremely high, affecting more than half of the samples. This suggests that while the bacteria are still vulnerable to the first-line treatments, they have already learned to defeat many of the stronger options. The study also tracked changes over time, noting that resistance to some "Access" drugs like nitrofurantoin and amikacin was slowly creeping up, while resistance to others was falling, indicating that the situation is not static but shifting in complex ways.
The study also explored how prescribing habits and bacterial resistance might be linked over time. By looking at the data month by month, the researchers noticed a pattern where resistance to certain "Watch" drugs seemed to rise a few months before resistance to specific "Access" drugs increased. This does not mean one caused the other directly, but it suggests that monitoring the use of stronger drugs could serve as an early warning system. If resistance to a powerful drug starts to climb, it might signal that resistance to the more common drugs will follow soon after. This kind of insight, drawn from routine digital records rather than specialized hospital labs, offers a new way to watch the health of a community.
This work highlights that the fight against drug-resistant bacteria requires looking beyond the hospital. The digital platform provided a window into the everyday reality of antibiotic use, revealing that the balance of power is shifting toward stronger medicines even as resistance to them grows. The findings suggest that simply tracking resistance in hospitals is not enough; understanding what happens in the community is essential for making smarter choices about which drugs to use. While the data comes from a specific digital network and cannot represent every person in the country, it proves that routine records from pharmacies and home labs can be a powerful tool for spotting trends early. By paying attention to these signals, health officials and doctors can adjust their strategies to protect the effectiveness of the medicines we rely on.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.